PetMed Express Delays Annual Report Amid Investigations
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Petmed Express ( (PETS) ) has issued an update.
On July 1, 2025, PetMed Express, Inc. announced a delay in filing its Annual Report for the fiscal year ended March 31, 2025, due to ongoing investigations into revenue recognition and promotional impacts. The Audit Committee is investigating anonymous reports concerning revenue timing and a $50 coupon promotion, but the company does not expect these issues to materially affect its financial results.
The most recent analyst rating on (PETS) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express shows a mixed financial performance with strong balance sheet stability but weak profitability and inconsistent cash flow. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics suggest the stock may be overvalued. The earnings call highlights progress in profitability and strategic investments, but challenges remain in sales and competitive pressures. Overall, the stock score reflects these combined factors, indicating moderate potential with significant risks.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions – including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives.
Average Trading Volume: 141,083
Technical Sentiment Signal: Sell
Current Market Cap: $67.96M
Learn more about PETS stock on TipRanks’ Stock Analysis page.
